½ÃÀ庸°í¼­
»óǰÄÚµå
1672649

Ç׿°Áõ¾à ½ÃÀå : ¾àÁ¦ À¯Çüº°, ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Anti-inflammatory Drugs Market, By Drug Type, By Application, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀåÀº 2025³â¿¡ 1,155¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 2,100¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 8.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 1,155¾ï 5,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR: 8.90% 2032³â °¡Ä¡ ¿¹Ãø 2,100¾ï 2,000¸¸ ´Þ·¯
µµÇ¥. 2025³â Áö¿ªº° Ç׿°Áõ¾à ½ÃÀå Á¡À¯À²(%)
Anti-inflammatory Drugs Market-IMG1

Ç׿°Áõ¾à´Â ü³» ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â ¾àÀÔ´Ï´Ù. °üÀýÅë, °üÀý¿° µî ¿°Áõ°ú ÅëÁõÀ» µ¿¹ÝÇÑ ÁúȯÀÇ Ä¡·á¿¡ ¸¹ÀÌ »ç¿ëµË´Ï´Ù. Ç׿°Áõ¾à´Â Å©°Ô ºñ½ºÅ×·ÎÀ̵强 Ç׿°Áõ¾à(NSAIDs), ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å/½ºÅ×·ÎÀ̵å, »ý¹°Á¦Á¦, ÀÎÅÍ·ùŲ Â÷´ÜÁ¦ µîÀ¸·Î ³ª´¹´Ï´Ù. À̺ÎÇÁ·ÎÆæ°ú ³ªÇÁ·Ï¼¾À» Æ÷ÇÔÇÑ ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦´Â ±× È¿°ú¿Í ÀϹÝÀǾàǰÀ¸·Î ±¸ÀÔÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¼Ò¿°ÁøÅëÁ¦ Áß ÇϳªÀÔ´Ï´Ù. °í·É Àα¸ Áõ°¡, °üÀý¿° ¹× ±âŸ ¿°Áõ¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¿°Áõ¼º Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÁ¦Ç° Ãâ½Ã µîÀº ÇâÈÄ Ç׿°Áõ¾à ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è Ç׿°Áõ¾à ½ÃÀåÀÇ ¼ºÀåÀº ³ëÀÎ Àα¸ Áõ°¡, °üÀý¿° ¹× ±âŸ ¿°Áõ¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¿°Áõ¼º Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÁ¦Ç° ½ÂÀÎ ¹× Ãâ½Ã µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ 3¾ï ¸í ÀÌ»óÀÇ »ç¶÷µéÀÌ ·ù¸¶Æ¼½º °üÀý¿°À» ¾Î°í ÀÖ´Â °ÍÀ¸·Î Ãß»êµË´Ï´Ù. Àα¸ °í·ÉÈ­·Î ÀÎÇØ °üÀý¿° ¹× ¿°Áõ¼º Áúȯ ȯÀÚ ¼ö´Â Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ Ç׿°Áõ¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¾à¹°ÀÇ ºÎÀÛ¿ë, ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á, °Ç°­º¸Á¶½Äǰ°ú °°Àº ´ëüǰÀÇ °³¹ß µîÀÇ ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÅÈï ±¹°¡Àº ±¹Á¦ÀûÀÎ ±â¾÷ÀÌ ÀÔÁö¸¦ È®´ëÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ Á¦Á¦ ±â¼úÀÇ ¿¬±¸°³¹ß°ú È¿´É°ú ¾ÈÀü¼ºÀ» °³¼±ÇÑ »ý¹°Á¦Á¦ÀÇ °³¹ßµµ »õ·Î¿î ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è Ç׿°Áõ¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è Ç׿°Áõ¾à ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Ç׿°Áõ¾à ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀåÀÇ Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • °³¿ä
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®

Á¦4Àå ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ±¸»ó
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)

  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°Áõ¾à(NSAlD)
  • ¸é¿ª ¼±ÅÃÀûÇ׿°Áõ À¯µµÃ¼(ImSAlD)
  • Ç׿°Áõ »ý¹°Á¦Á¦
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å

Á¦6Àå ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀå, ¿ëµµº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • °üÀý¿°
  • ¸¸¼º Æó¼â¼º ÆóÁúȯ(COPD)
  • ´Ù¹ß¼º °æÈ­Áõ
  • ¿°Áõ¼ºÀåÁúȯ(IBD)
  • Åëdz
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • °æ±¸
  • µµÆ÷
  • ÁÖ»ç
  • ÈíÀÔ

Á¦8Àå ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°èÀÇ Ç׿°Áõ¾à ½ÃÀå, Áö¿ªº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
      • GCC ±¹°¡
      • À̽º¶ó¿¤
      • ±âŸ Áßµ¿
    • ¾ÆÇÁ¸®Ä«
        • ºÏ¾ÆÇÁ¸®Ä«
        • Áß¾Ó¾ÆÇÁ¸®Ä«
        • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

    Á¦10Àå °æÀï ±¸µµ

    • ±â¾÷ °³¿ä
      • Pfizer, Inc.
      • Johnson &Johnson
      • Merck &Co., Inc.
      • GlaxoSmithKline plc
      • Novartis AG
      • Eli Lilly and Company
      • Sanofi
      • AbbVie Inc.
      • Amgen Inc.
      • AstraZeneca PLC
      • Roche Holding AG
      • Bristol Myers Squibb Company
      • Teva Pharmaceutical Industries Ltd.
      • Bayer AG
      • Boehringer Ingelheim International GmbH
      • Gilead Sciences, Inc.
      • Horizon Therapeutics plc

    Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

    • ¿î¸íÀÇ ¼ö·¹¹ÙÄû
    • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
    • COM(Coherent Opportunity Map)

    Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

    • Âü°í ¹®Çå
    • Á¶»ç ¹æ¹ý
    KSA 25.04.02

    Global Anti-Inflammatory Drugs Market is estimated to be valued at USD 115.55 Bn in 2025 and is expected to reach USD 210.02 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

    Report Coverage Report Details
    Base Year: 2024 Market Size in 2025: USD 115.55 Bn
    Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
    Forecast Period 2025 to 2032 CAGR: 8.90% 2032 Value Projection: USD 210.02 Bn
    Figure. Anti-Inflammatory Drugs Market Share (%), By Region 2025
    Anti-inflammatory Drugs Market - IMG1

    Anti-inflammatory drugs are medications that reduce inflammation in the body. These are commonly used to treat joint pain, arthritis, and other conditions associated with inflammation and pain. Some of the major classes of anti-inflammatory drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids/steroids, biologics, and interleukin blockers. NSAIDs including ibuprofen and naproxen are among the most commonly used anti-inflammatory medications due to their effectiveness and OTC availability. Growing geriatric population, rising prevalence of arthritis and other inflammatory diseases, increasing awareness about inflammatory conditions, and new product launches can drive the anti-inflammatory drugs market growth in the near future.

    Market Dynamics:

    Global anti-inflammatory drugs market growth is driven by factors such as growing geriatric population, rising prevalence of arthritis and other inflammatory diseases, increasing awareness about inflammatory conditions, new product approvals and launches. As per estimates, over 300 million people suffer from rheumatoid arthritis worldwide. The number of arthritis and inflammatory disease cases is projected to increase significantly due to aging population. This can boost demand for anti-inflammatory drugs for treatment of these diseases. However, factors such as adverse side effects of medications, patent expiries of blockbuster drugs, and development of alternatives like nutraceuticals can hamper the market growth. Emerging economies can offer lucrative opportunities for international players to expand their presence. Ongoing research on innovative formulation technologies and development of biologics with improved efficacy and safety profile can also offer new opportunities.

    Key features of the study:

    • This report provides in-depth analysis of the global anti-inflammatory drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
    • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
    • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
    • It profiles key players in the global anti-inflammatory drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
    • Key companies covered as a part of this study include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, Abbott, Zydus Cadila, Sanofi, Merck, Roche, and Bayer
    • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
    • Global anti-inflammatory drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
    • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-inflammatory drugs market

    Detailed Segmentation-

    • By Drug Type
      • Nonsteroidal Anti-inflammatory Drugs (NSAlDs)
      • Immune Selective Anti-inflammatory Derivatives (ImSAlDs)
      • Anti-inflammatory Biologics
      • Corticosteroids
    • By Application
      • Arthritis
      • Chronic Obstructive Pulmonary Disease (COPD)
      • Multiple Sclerosis
      • Inflammatory Bowel Disease (IBD)
      • Gout
      • Others
    • By Route of Administration
      • Oral
      • Topical
      • Injection
      • Inhalation
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Region:
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East
      • Africa
    • Company Profiles:
      • Pfizer, Inc.
      • Johnson & Johnson
      • Merck & Co., Inc.
      • GlaxoSmithKline plc
      • Novartis AG
      • Eli Lilly and Company
      • Sanofi
      • AbbVie Inc.
      • Amgen Inc.
      • AstraZenica PLC
      • Roche Holding AG
      • Bristol Myers Squibb Company
      • Teva Pharmaceutical Industries Ltd.
      • Bayer AG
      • Boehringer Ingelheim International GmbH
      • Gilead Sciences, Inc.
      • Horizon Therapeutics plc

    Table of Contents

    1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

    2. Market Purview

    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Application
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)

    3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Acquisitions and Partnerships Scenario
    • Funding and Investments
    • PEST Analysis
    • Porter's Analysis

    4. Global Anti-inflammatory Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

    • Overall Impact
    • Government Initiatives
    • COVID-19 Impact on the Market

    5. Global Anti-inflammatory Drugs Market, By Drug Type, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Nonsteroidal Anti-inflammatory Drugs (NSAlDs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Immune Selective Anti-inflammatory Derivatives (ImSAlDs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Anti-inflammatory Biologics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Corticosteroids
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    6. Global Anti-inflammatory Drugs Market, By Application, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Arthritis
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Chronic Obstructive Pulmonary Disease (COPD)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Multiple Sclerosis
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Inflammatory Bowel Disease (IBD)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Gout
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    7. Global Anti-inflammatory Drugs Market, By Route of Administration, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Topical
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Injection
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Inhalation
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    8. Global Anti-inflammatory Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    9. Global Anti-inflammatory Drugs Market, By Region, 2020 - 2032, (USD Bn)

    • Introduction
      • Market Share Analysis, By Region, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, For Region, 2021-2032
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
        • North Africa
        • Central Africa
        • South Africa

    10. Competitive Landscape

    • Company Profiles
      • Pfizer, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Johnson & Johnson
      • Merck & Co., Inc.
      • GlaxoSmithKline plc
      • Novartis AG
      • Eli Lilly and Company
      • Sanofi
      • AbbVie Inc.
      • Amgen Inc.
      • AstraZeneca PLC
      • Roche Holding AG
      • Bristol Myers Squibb Company
      • Teva Pharmaceutical Industries Ltd.
      • Bayer AG
      • Boehringer Ingelheim International GmbH
      • Gilead Sciences, Inc.
      • Horizon Therapeutics plc

    11. Analyst Recommendation

    • Wheel of Fortune
    • Analyst View
    • Coherent Opportunity Map

    12. References and Research Methodology

    • References
    • Research Methodology
    • About Us and Sales Contact
  • ºñ±³¸®½ºÆ®
    0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
    »óǰ ºñ±³Çϱâ
    Àüü»èÁ¦